Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction Pilot Study
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects
of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL),
microbiome diversity, leaky gut, and systemic inflammation in patients with 20 older patients
with heart failure with preserved ejection fraction (HFpEF).